Revlimid generic
Revlimid is an anti-cancer drug owned by Bristol Myers Squibb. It contains lenalidomide as its active ingredient and was first authorized for market use on 27 December, 2005. The drug is available in capsule; oral dosage forms and comes with a total of 15 drug patents, 12 of which are expired.
When will Revlimid generic be available?
The release of generic versions of Revlimid is anticipated after 08 March, 2028 which is the expiration date of the last patent. This provides other pharmaceutical manufacturers the opportunity to produce and sell cheaper, generic versions of the drug.
Revlimid uses
Revlimid is used for the treatment of various conditions including multiple myeloma, in combination with dexamethasone, for patients who have not received prior treatment for this disease. It is also used for treating transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality. In addition, it is used for treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed, after two prior therapies, one of which included Bortezomib. Other uses include maintenance treatment following autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients, treatment of previously treated marginal zone lymphoma and follicular lymphoma in combination with a Rituximab product.
Revlimid patent expiration
Revlimid has 15 drug patents, with 12 of those already expired. The last Revlimid patent is expected to expire on 08 March, 2028, paving the way for generic versions of the drug. Below are the details of the patents: